Akari Therapeutics, Plc

NASDAQ: AKTX · Healthcare · Biotechnology

PublicHQ Tampa, FL · HillsboroughCIK 0001541157Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH 43DQ —GM —SS 42

v0.1 · 35/100 weight · pillars only

↑ balance-sheet leverage, listing tenure · ↓ workforce scale, Piotroski F

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$17.3M

Employees

as of 2026-07-19

Market cap

$15.3M

as of 2026-07-19

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$17.3M-$17.3M2025

Operating income-$17.3M-$17.3M2025

Total assets$47.9M$47.9M2025

Liabilities$19.6M$19.6M2025

Equity$28.3M$28.3M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Akari Therapeutics, Plc’s financial profile?

Akari Therapeutics, Plc earned -$17.3M in FY2025 net income.

Peers · Healthcare

ProMIS Neurosciences, Inc.——ImpediMed Limited——Optimi Health Corp.——CS Diagnostics Corp.——BioVie Inc.——Passage Bio, Inc.——

Neighbors

Hillsborough →

Primo Brands Corporation$6.7B55C The Mosaic Company$12.1B61C Slide Insurance Holdings, Inc. Common Stock$1.2B67B HCI Group, Inc.$900.9M78B+The Baldwin Insurance Group, Inc.$1.5B42D Exzeo Group, Inc.$217.0M54D

Key facts

CEOAbizer Gaslightwala

SectorHealthcare

IndustryBiotechnology

HeadquartersTampa, FL

ExchangeNASDAQ: AKTX

Employees6

IPO date2014-01-06

Latest filings

8-K2026-08-13 10-Q2026-08-13 8-K2026-07-02 8-K2026-06-26 DEF 14A2026-06-04 8-K2026-05-22 10-Q2026-05-19 10-K2026-03-30

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.